ARQL ArQule, Inc.

1.01
+0  (1%)
Previous Close 1.00
Open 1.00
Price To book 3.00
Market Cap 71.85M
Shares 71,136,000
Volume 18,977
Short Ratio 2.07
Av. Daily Volume 216,369

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17759305
  2. 8-K - Current report 17754891
  3. 8-K - Current report 17751674
  4. 8-K - Current report 17714174
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17678993

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment completed. Phase 3 trial planned for 3Q 2017.
ARQ 087
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer

Latest News

  1. ArQule To Report First Quarter 2017 Financial Results On May 3, 2017
  2. ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
  3. ETFs with exposure to ArQule, Inc. : April 5, 2017
  4. ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
  5. ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
  6. ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  7. ArQule, Inc. :ARQL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  8. Edited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT
  9. ArQule reports 4Q loss
  10. ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
  11. ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
  12. ArQule Liver Cancer Drug Fails Phase 3 Trial
  13. ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?
  14. Sabre Corp., L Brands Dip into Friday’s 52-Week Low Club
  15. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
  16. ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017
  17. ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
  18. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
  19. ETFs with exposure to ArQule, Inc. : December 21, 2016
  20. How ArQule, Inc. (ARQL) Stacks Up Against Its Peers